{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stewart MJ"],"funding":["U.S. Department of Defense (DOD) Chronic Pain Management Research Program (CPMRP) Investigator-Initiated Research Award","NHLBI NIH HHS","National Institutes of Health"],"pagination":["3326"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9971260"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["The growing opioid use and overdose crisis in the US is closely related to the abuse of pain medications. Particularly for postoperative pain (POP), ~ 310 million major surgeries are performed globally per year. Most patients undergoing surgical procedures experience acute POP, and ~ 75% of those with POP report the severity as moderate, severe, or extreme. Opioid analgesics are the mainstay for POP management. It is highly desirable to develop a truly effective and safe non-opioid analgesic to treat POP and other forms of pain. Notably, microsomal prostaglandin E2 (PGE<sub>2</sub>) synthase-1 (mPGES-1) was once proposed as a potentially promising target for a next generation of anti-inflammatory drugs based on studies in mPGES-1 knockouts. However, to the best of our knowledge, no studies"],"journal":["Scientific reports"],"pubmed_title":["Analgesic effects of a highly selective mPGES-1 inhibitor."],"pmcid":["PMC9971260"],"funding_grant_id":["W81XWH2211000","U01 HL152392"],"pubmed_authors":["Loftin CD","Weaver LM","Kyomuhangi A","Zhan CG","Stewart MJ","Ding K","Zheng F"],"additional_accession":[]},"is_claimable":false,"name":"Analgesic effects of a highly selective mPGES-1 inhibitor.","description":"The growing opioid use and overdose crisis in the US is closely related to the abuse of pain medications. Particularly for postoperative pain (POP), ~ 310 million major surgeries are performed globally per year. Most patients undergoing surgical procedures experience acute POP, and ~ 75% of those with POP report the severity as moderate, severe, or extreme. Opioid analgesics are the mainstay for POP management. It is highly desirable to develop a truly effective and safe non-opioid analgesic to treat POP and other forms of pain. Notably, microsomal prostaglandin E2 (PGE<sub>2</sub>) synthase-1 (mPGES-1) was once proposed as a potentially promising target for a next generation of anti-inflammatory drugs based on studies in mPGES-1 knockouts. However, to the best of our knowledge, no studies","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-26T10:18:01.365Z","creation":"2025-04-06T13:19:29.154Z"},"accession":"S-EPMC9971260","cross_references":{"pubmed":["36849491"],"doi":["10.1038/s41598-023-30164-3"]}}